ArticleAnnals of internal medicine2010
Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer.
Article in Annals of internal medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review.PharmacoEconomics · 2023Pooled it
- Remote Bone Health Service for Osteoporosis Screening in High-Risk Men: A Cluster Randomized Clinical Trial.JAMA internal medicine · 2025Trial
- Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.Clinical journal of the American Society of Nephrology : CJASN · 2011Trial
- Cost-effectiveness analysis of low bone mass prevention in Chinese older men with excessive alcohol consumption: a modelling study.BMJ open · 2026Article
- Cost-effectiveness analysis of prostate-specific antigen screening in China: a middle-income population-based microsimulation study.The Lancet regional health. Western Pacific · 2025Article
- Osteoporosis in men-East and West: Can the twain meet? A perspective from Asia.Osteoporosis and sarcopenia · 2024Review
- Evidence-Based Guideline for the management of osteoporosis in men.Nature reviews. Rheumatology · 2024Review
- Cost-effectiveness of Screening for Osteoporosis in Older Men With a History of Falls.JAMA network open · 2020Article
- Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA.BMJ open · 2018Article
- The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.BJU international · 2018Article
- The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.Oncotarget · 2017Review
- Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update.Prostate cancer and prostatic diseases · 2017Review
- Quality of care provided to prostate cancer (PC) patients for prevention and treatment of osteoporosis induced by androgen deprivation therapy (ADT).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.Clinical genitourinary cancer · 2016Article
- Cost-effectiveness of fracture prevention in rural women with limited access to dual-energy X-ray absorptiometry.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- Bone health management in men undergoing ADT: examining enablers and barriers to care.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Article
- The impact of bone mineral density testing, fracture assessment, and osteoporosis education in men treated by androgen deprivation for prostate cancer: a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.Current oncology (Toronto, Ont.) · 2014Article
- Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.Journal of general internal medicine · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAndrogen deprivation therapy (ADT) increases the risk for fractures in patients with prostate cancer.
objectiveTo assess the cost-effectiveness of measuring bone mineral density (BMD) before initiating ADT followed by alendronate therapy in men with localized prostate cancer.
designMarkov state-transition model simulating the progression of prostate cancer and the incidence of hip fracture. DATA SOURCES: Published literature. TARGET POPULATION: A hypothetical cohort of men aged 70 years with locally advanced or high-risk localized prostate cancer starting a 2-year course of ADT after radiation therapy. TIME HORIZON: Lifetime. PERSPECTIVE: Societal.
interventionNo BMD test or alendronate therapy, a BMD test followed by selective alendronate therapy for patients with osteoporosis, or universal alendronate therapy without a BMD test. OUTCOME MEASURES: Incremental cost-effectiveness ratio (ICER), measured by cost per quality-adjusted life-year (QALY) gained. RESULTS OF BASE-CASE ANALYSIS: The ICERs for the strategy of a BMD test and selective alendronate therapy for patients with osteoporosis and universal alendronate therapy without a BMD test were $66,800 per QALY gained and $178,700 per QALY gained, respectively. RESULTS OF SENSITIVITY ANALYSES: The ICER for universal alendronate therapy without a BMD test decreased to $100,000 per QALY gained, assuming older age, a history of fractures, lower mean BMD before ADT, or a lower cost of alendronate. LIMITATIONS: No evidence shows that alendronate reduces actual fracture rates in patients with prostate cancer who receive ADT. The model predicted fracture rates by using data on the surrogate BMD end point.
conclusionIn patients starting adjuvant ADT for locally advanced or high-risk localized prostate cancer, a BMD test followed by selective alendronate for those with osteoporosis is a cost-effective use of resources. Routine use of alendronate without a BMD test is justifiable in patients at higher risk for hip fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.